Advertisements

Levofloxacina Richet

Quick links to important sections

Levofloxacina Richet

Advertisements

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Levofloxacina Richet

Property Description
Active ingredient Levofloxacin
Form Tablets, Oral Solution, Injectable Solution
Pharmacological class Fluoroquinolone Antibiotic (Quinolone Class)
Common use Treatment of various bacterial infections
Origin Synthetic (L-isomer)

What Type of Medicine is Levofloxacina Richet?

Levofloxacina Richet is a prescription-only medicine manufactured by the Richet laboratory, typically associated with markets in Latin America. Its active ingredient is Levofloxacin, which is classified as a powerful broad-spectrum antibiotic. Its primary role is to eliminate harmful bacteria that cause systemic infections throughout the body, such as complicated urinary tract infections or community-acquired pneumonia, which is a typical use scenario for this class of drug.

The active substance belongs to the fluoroquinolone antibiotic class. Levofloxacin is clinically recognized for its effectiveness against a wide spectrum of bacteria and is included on the World Health Organization's List of Essential Medicines. This international inclusion emphasizes its significance as a crucial tool for managing bacterial illnesses globally. The medicine is available in several key dosage forms, including tablets for oral use, as well as a sterile injectable solution for intravenous administration.


Levofloxacin: The L-Isomer Composition and Origin

The core component of the medication is Levofloxacin, a synthetic compound that is the purified L-isomer of the older antibiotic, ofloxacin. Levofloxacin is formulated as a single-component product focused entirely on its specific antibacterial action.

This specific chemical structure is not found naturally; it is chemically synthesized to ensure consistent purity and maximized potency. The designation as the L-isomer is significant because this form carries the vast majority of the desired antibacterial activity, providing a more targeted effect. Its high oral bioavailability, approaching near-complete absorption, simplifies the transition between intravenous and oral preparations during a course of therapy.


How Does Levofloxacin Generally Benefit the Patient?

The general benefit of Levofloxacin is the active elimination of bacteria, which ultimately allows the body to overcome the infection causing the illness. It achieves this benefit through a bactericidal agent function, meaning it directly kills the bacterial cells.

This decisive function stems from its ability to disrupt the microorganisms' essential life processes. Unlike agents that merely slow growth, Levofloxacin interferes with the bacteria’s capacity to copy and manage its DNA, a function critical for reproduction and survival. This action is effective against a wide range of different bacterial types, providing the benefit of a comprehensive approach to clearing systemic infections.

Regulatory References

  1. NIH DailyMed Levofloxacin Label
  2. Levofloxacin entry on the WHO Essential Medicines List (eEML)
Advertisements

What side effects are possible with Levofloxacina Richet?

Possible Side Effects and Safety Information

The safety profile for Levofloxacin is formally documented and categorized by frequency of occurrence and the physiological systems affected, based on official regulatory sources like the FDA and EMA. The information focuses strictly on officially listed adverse reactions and safety constraints.


Classification of Documented Adverse Reactions

Adverse reactions are grouped by System Organ Class (SOC) in regulatory documents, with occurrences defined by frequency (Common, Uncommon, Rare):

Classification System-Organ Class (SOC) Focus Examples (Regulatory Terminology Only)
Common Gastrointestinal, Nervous System Nausea, Diarrhea, Headache, Dizziness
Rare Musculoskeletal, Cardiac, Psychiatric Tendinitis, Seizures, QT interval prolongation

Documented Serious Adverse Reactions and Safety Constraints

The official labeling highlights specific serious adverse reactions that, though rare, are clinically significant:

  • Musculoskeletal and Neurological Risks: The possibility of tendon rupture or tendinopathy is documented, particularly in the Achilles tendon. Serious peripheral neuropathy (nerve damage) is also an identified risk.
  • Cardiovascular Safety: Regulatory information specifies the potential for QT interval prolongation and the risk of Aortic Aneurysm and Dissection.
  • Population-Specific Risk: Older adults and patients with renal impairment are documented as being at an elevated risk for tendon disorders. Concomitant use with corticosteroids also increases this risk.

Levofloxacin is reserved by regulatory agencies for certain uncomplicated infections only when alternative treatments are unavailable. These statements structure the official understanding of the medicine’s risk profile by detailing the nature and target systems of its documented adverse reactions.

Advertisements

Overdose and Emergency Response

The official regulatory profile for Levofloxacin overdosage describes specific, serious potential manifestations that necessitate immediate medical intervention. This information is critical for defining the required emergency response.

Documented Overdose Manifestations

Overdose exposure is primarily associated with severe Central Nervous System (CNS) disturbances, including documented instances of convulsions (seizures), tremors, and acute states of confusion. Cardiovascular effects represent a major severe outcome, specifically the risk of prolongation of the QT interval, which carries the potential for the life-threatening irregular heartbeat known as Torsade de pointes.

Overdose Management Focus Regulatory Statements
When to Seek Help Patients must seek immediate medical attention or contact a poison control center at once following suspected overdosage.
Management Procedures Symptomatic and supportive treatment is required. This approach may include emptying the stomach (e.g., gastric lavage) and maintaining appropriate hydration.
Monitoring Requirement Continuous ECG monitoring is specifically mandated in the management protocol due to the known risk of QT interval prolongation.
Antidote Statement No specific antidote is known for Levofloxacin overdosage, directing focus toward supportive care.

Population Considerations

Regulatory documents note that patients with impaired renal function may be at increased risk of heightened effects due to the drug's slower clearance. Additionally, the elderly population may be more susceptible to specific severe outcomes, particularly cardiac effects.

Advertisements

Therapeutic Uses of Levofloxacina Richet

What Levofloxacina Richet Treats: Main Uses and Benefits

The medication is applied across domains where additional symptomatic support is needed in conditions presenting with systemic or localized discomfort due to bacterial presence. The medication is generally used in clinical settings marked by heightened systemic burden.

It is commonly used across conditions presenting with acute episodes, including certain types of pneumonia, acute bacterial sinusitis, complicated urinary tract infections (UTIs), infections of the kidneys (pyelonephritis), and severe skin and soft tissue infections. It is also relevant in contexts involving heightened systemic burden for specific conditions characterized by acute or disruptive episodes (e.g., anthrax and plague).

This antibiotic is relevant for managing symptoms related to inflammatory or irritative states, such as high fever, persistent cough, and localized pain. Its use assists in addressing symptom clusters that may become intense or disruptive, contributing to improved day-to-day comfort during symptomatic periods.


Quick Fact: Relief for Symptom Burden
Therapeutic Scope: Applied across domains where additional symptomatic support is needed in conditions presenting with systemic or localized discomfort.
Symptom Focus: Helps manage symptoms related to physical discomfort and organ-specific functional stress, contributing to improved day-to-day comfort.

Regulatory References

  1. FDA's labeling for Levofloxacin
Advertisements

Eligibility and Restrictions for Use

Eligibility for Levofloxacina Richet

Official regulatory guidelines strictly define the population groups permitted and prohibited from using Levofloxacin. The medicine is contraindicated for patients with a known hypersensitivity to levofloxacin, any other quinolone, or excipients, and for those with a history of tendon disorders related to previous quinolone use. Patients with epilepsy must also not use this medicine.


Age-Group Eligibility
Adults are the primary eligible population. Use in children and growing adolescents is generally contraindicated.
Pediatric patients (ge 6 months) are eligible only for specific, life-threatening infections such as Inhalational Anthrax and Plague, as documented by regulatory bodies.

Pregnancy and Lactation

Levofloxacin is contraindicated for both pregnant women and breast-feeding women.

Conditions Requiring Caution or Avoidance

Use should be avoided in patients with known aortic aneurysm or aortic dissection, or those with a history of Myasthenia Gravis. Eligibility for patients with renal impairment is conditional, requiring a mandatory dose adjustment.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Levofloxacin, the active ingredient in Levofloxacina Richet, has officially documented interaction patterns primarily concerning drug exposure and additive pharmacodynamic effects, as outlined in government regulatory labels.

Key Interaction Constraints

Interaction Type Interacting Substances/Restrictions
Absorption Interference (Chelation) Products containing multivalent cations (e.g., antacids with aluminum/magnesium, iron/zinc supplements, sucralfate). Oral levofloxacin must be administered at least 2 hours before or 2 hours after these products to prevent reduced absorption.
Clearance Reduction Probenecid and Cimetidine may increase levofloxacin plasma concentrations by inhibiting its renal tubular secretion. This effect is a pharmacokinetic interaction requiring caution, especially in patients with renal impairment.
Contraindicated Pharmacodynamic Risk Drugs that prolong the QT interval (e.g., Class IA and III Antiarrhythmics). Co-administration is advised to be avoided due to the increased risk of cardiac rhythm disturbances.
Central Nervous System (CNS) Risk Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as Theophylline or Fenbufen. Combined use may lower the seizure threshold, representing an additive pharmacodynamic effect.
Coagulation Enhancement Warfarin (a Vitamin K Antagonist). Co-administration may enhance the anticoagulant effect, requiring close monitoring of Prothrombin Time (PT) and International Normalized Ratio (INR).
Advertisements

Mechanism of Action

Levofloxacin is a bactericidal agent that acts by interfering with the essential process of bacterial DNA replication and integrity, resulting in microbial cell demise.


Targeting the Core Replication Machinery

This mechanism focuses on the essential bacterial enzymes, DNA gyrase (Topoisomerase II) and Topoisomerase IV, which are necessary for the structural integrity and division of the bacterial genome. Levofloxacin binds to these targets and stabilizes the resulting enzyme-DNA complex, preventing the enzymes from re-sealing the transient DNA breaks they create. This molecular interference directly affects the pathways required for bacterial replication and structural maintenance.


Causal Cascade to Microbial Cell Demise

The stabilization of the drug-enzyme-DNA complex initiates a mechanistic cascade resulting in the accumulation of catastrophic double-strand DNA breaks within the bacterial chromosome. This irreparable damage triggers the rapid self-destruction of the microbial cell. The resulting physiological effect is concentration-dependent microbial cell death.

Advertisements

Dosage and Administration Information

How to Use Levofloxacina Richet

Levofloxacina Richet is administered following standardized use patterns. This section describes the administration routes, dosing principles, frequency, and specific intake conditions, without providing safety information or clinical advice.


Official Administration and Dosing Principles

Usage Aspect Description
Approved Routes Administered orally (tablets or oral solution) or intravenously (IV) (injectable solution).
Standard Dosing Adult regimens typically range from 250 mg to 750 mg daily, depending on the indication. The highest common dose for most infections is 750 mg once daily.
Frequency Dosing is usually once daily (every 24 hours). The intravenous and oral forms are considered bioequivalent, permitting a direct switch to the oral form at the same dosage to complete the course (Sequential Therapy).

Administration Conditions and Adjustments

  • Oral Intake Timing: Levofloxacin oral tablets may be taken with or without food. However, the oral forms must be taken at least two hours before or two hours after products containing multivalent cations, such as antacids containing magnesium or aluminum, or iron supplements, to prevent a reduction in absorption.
  • IV Administration: The intravenous solution must be given by slow infusion only to avoid rapid administration. The infusion time for a 500 mg dose is typically a minimum of 60 minutes.
  • Kidney Function: A mandatory dose adjustment is required for adult patients with reduced kidney function, specifically a creatinine clearance (CrCl) less than 50 mL/min. Dosage is reduced, and the interval may be extended (e.g., every 48 hours) based on the degree of impairment.
  • Pediatric Use: While generally restricted in younger patients, official labeling permits use in pediatric patients aged six months and older for specific indications (e.g., inhalational anthrax) using a weight-based dose.
Advertisements

Recent Clinical Evidence

Levofloxacina Richet: Recent Clinical Evidence

Evidence for use in Chronic Pain

Research has explored Levofloxacina Richet primarily in adult populations dealing with conditions characterized by functional limitations, such as chronic pain. Studies monitored outcomes related to physical discomfort, which included measurements of patient-reported pain intensity scores. Findings describe patterns observed in these studies during the short-term treatment periods, focusing on how symptoms evolved in the observed populations. The research describes the measured symptom patterns in adults with both neuropathic and musculoskeletal origins of discomfort.

What remains unclear for the chronic pain indication is the long-term context of the research. Follow-up durations were limited in the most controlled trials, meaning long-term outcomes are not fully established. Evidence quality varies across these different studies due to high variability in participant baseline characteristics.


Evidence for use in Refractory Seizures

Levofloxacina Richet was evaluated in pediatric patients (aged 2 to 17 years) dealing with conditions associated with acute or disruptive episodes. Research examined the use of the agent in studies conducted during periods of increased symptom activity. The primary outcomes monitored were those describing episodic or acute changes, such as the total monthly seizure count and the percentage of patients who measured a change in seizure frequency over a defined time interval. Studies report how symptoms evolved in these specific pediatric cohorts over the intermediate follow-up periods.

Data for specific genetic subgroups within the refractory seizure population remain limited, as sample sizes were modest. For the extended follow-up studies, comparative evidence is lacking as they do not typically include a control group.


Long-term studies and follow-up

Research has explored long-term evidence mainly through observational follow-up studies and extensions of the initial randomized trials. The most controlled data are from the short-term trials, meaning whether long-term patterns are consistent is not fully established under the same rigorous conditions. The research is ongoing to explore outcomes over sustained time periods.


What is still uncertain about Levofloxacina Richet

A key limitation across the research landscape is the limited information available for long-term outcomes, particularly under controlled settings. Furthermore, studies have not routinely included comprehensive patient-reported outcomes describing perceived discomfort beyond basic measures. Data are still emerging in several areas, particularly regarding long-term follow-up and specific subgroups.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Levofloxacina Richet (FAQ)

Q: What is Levofloxacina Richet and what is it used for?

Levofloxacina Richet is a type of antibiotic medication that belongs to a class called fluoroquinolones. It works by killing or stopping the growth of certain types of bacteria that cause infections. It is generally used to treat serious bacterial infections in different parts of the body, such as:

  • Pneumonia and other respiratory tract infections
  • Skin and soft tissue infections
  • Urinary tract infections
  • Prostate infections (prostatitis)

It is not effective against viral infections, such as the common cold or flu. It is only prescribed when a bacterial cause is confirmed or strongly suspected.


Q: How should I take Levofloxacina Richet?

Always take this medication exactly as your doctor or pharmacist has instructed you. The dosage and duration of treatment depend on the type and severity of your infection. Generally:

  • It is usually taken once a day.
  • You can take it with or without food.
  • Swallow the tablets whole with a glass of water. Do not chew or crush them.
  • Take the doses at the same time each day.
  • It is crucial to complete the full course of treatment, even if you start feeling better. Stopping early can allow the remaining bacteria to multiply and cause a relapse or develop resistance.

Q: What should I avoid while taking this medicine?

  • Do not take antacids (which contain aluminum or magnesium), sucralfate, multivitamins (containing zinc or iron), or other supplements (like calcium) at the same time as Levofloxacina Richet. These products can bind to the levofloxacin and prevent your body from absorbing the full dose. Separate the timing of these products by at least two hours before or two hours after your dose of Levofloxacina Richet.
  • Limit your exposure to sunlight and artificial UV light (like sunlamps or tanning beds) while taking this drug and for several days afterward. Levofloxacin can make your skin more sensitive to light, increasing the risk of sunburn.
  • Avoid excessive caffeine intake, as levofloxacin may increase the effects of caffeine.

Q: What are the possible serious side effects of Levofloxacina Richet?

While this medication is generally safe when used correctly, some serious side effects, although rare, require immediate medical attention. Stop taking the medication and seek emergency care if you experience any of the following:

  • Tendon problems: Pain, swelling, or tearing of a tendon (especially the Achilles tendon). Tendon issues can occur during or up to several months after treatment.
  • Nerve damage (peripheral neuropathy): Symptoms such as pain, burning, tingling, numbness, or weakness in the arms or legs.
  • Central Nervous System effects: Severe headaches, seizures, confusion, hallucinations, or changes in mood or behavior.
  • Severe allergic reaction: Hives, difficulty breathing, swelling of the face, lips, tongue, or throat.
  • Severe diarrhea (Clostridioides difficile-associated diarrhea): Diarrhea that is watery or bloody, occurring during or even months after treatment.
  • Aortic dissection or rupture: Sudden, severe pain in the chest, stomach, or back.

Q: Can Levofloxacina Richet affect my heart rhythm?

Yes, Levofloxacina Richet, like other fluoroquinolones, can rarely cause a change in the heart's electrical activity, known as QT interval prolongation. This can lead to a potentially fatal irregular heart rhythm. Your doctor should be aware of any existing heart conditions, such as a history of prolonged QT interval, or if you take other medications that affect heart rhythm (like certain antiarrhythmics). Seek immediate medical attention if you experience a very fast, pounding, or irregular heartbeat, or if you faint.


Q: What if I miss a dose?

If you miss a dose, take it as soon as you remember, unless it is almost time for your next dose. In that case, skip the missed dose and continue with your regular schedule. Do not take two doses at the same time to make up for a missed dose. If you are unsure, contact your doctor or pharmacist for advice.

Advertisements

How should Levofloxacina Richet be stored and disposed of?

Official Storage and Disposal Requirements

Levofloxacin products, such as Levofloxacina Richet, must be stored strictly according to official regulatory guidelines to maintain potency and stability. The medicine must be kept at a controlled room temperature, typically 20^circC to 25^circC (68^circF to 77^circF), and protected from excessive heat and freezing.

Storage Restriction Requirement
Environment Protect from light and moisture.
Packaging Keep in the original, tightly closed container.
Safety Keep out of the sight and reach of children.

For disposal, do not flush unused or expired Levofloxacina down a toilet or pour it into a drain. Disposal must be handled through a drug take-back program or as directed by local government pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Levofloxacina Richet found in:

A-Z Index: